Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Resources and References Resources Whom to Treat CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” (MMWR 2000;49[No. RR-6]). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . CDC. Core Curriculum on Tuberculosis (2004) [Division of Tuberculosis Elimination Web site]. Updated October 2004. Available at: http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm Treatment Regimens and Dosages CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” (MMWR 2000;49[No. RR-6]). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf CDC. “Update: Adverse Event Data and Revised American Thoracic Society (ATS)/Centers for Disease Control and Prevention (CDC) Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection” (MMWR 2003;52[No. 31]). Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm CDC. Core Curriculum on Tuberculosis (2004) [Division of Tuberculosis Elimination Web site]. Updated October 2004. Available at: http://www.cdc.gov/tb/webcourses/CoreCurr/index.htm CDC. “Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. MMWR 2011; 60(48); 1650-1653. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a3_w CDC. Errata: Vol. 60, No. 48. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6104a7.htm?s_cid=mm6104a7_w CDC. “The 12 Dose Regimen for Latent TB Infection”. Patient Brochure. Available at: http://www.cdc.gov/tb/publications/pamphlets/12DoseLTBITreatmentbrochure8.5x11.pdf Side Effects and Adverse Reactions CDC. “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection” (MMWR 2000;49[No. RR-6]:26–29, 38–39). Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4906.pdf . A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Treatment of Latent Tuberculosis Infection Revised November 2012 8.24
National Tuberculosis Controllers Association–National Tuberculosis Nurse Consultant Coalition. Tuberculosis Nursing: A Comprehensive Guide to Patient Care (Atlanta, GA;1997:47–51, 63–64). CDC. Module 4: “Treatment of Tuberculosis and Tuberculosis Infection” (Self- Study Modules on Tuberculosis [Division of Tuberculosis Elimination Web Site]; 2008). Available at: http://www.cdc.gov/tb/education/ssmodules/default.htm Saukkonen, J. Et al. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. Am J Respir Crit Care Med. 2006:174, 935-952. Available at http://ajrccm.atsjournals.org/cgi/reprint/174/8/935.pdf Adherence CDC. Module 9: “Patient Adherence to Tuberculosis Treatment” (Self-Study Modules on Tuberculosis. Division of Tuberculosis Elimination Web Site; 1999). Available at: http://www.cdc.gov/tb/education/ssmodules/module9/ss9contents.htm Module is entirely devoted to assessing and promoting adherence. It covers the many areas that need to be addressed, such as: Case management: assigning responsibility to the healthcare worker Communication and problem-solving skills Education of the patient Using interpreters when needed Using incentives (rewards) and enablers (things that remove barriers for patients) Using directly observed therapy (DOT) CDC. Improving Patient Adherence to Tuberculosis Treatment. (1994) National Tuberculosis Controllers Association–National Tuberculosis Nurse Consultant Coalition. Tuberculosis Nursing: A Comprehensive Guide to Patient Care (Atlanta, GA; 1997:69–84). A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Treatment of Latent Tuberculosis Infection Revised November 2012 8.25
- Page 127 and 128: After the initial phase (first two
- Page 129 and 130: Extrapulmonary Tuberculosis The bas
- Page 131 and 132: Resources and References Resources
- Page 133 and 134: Diagnosis of Latent Tuberculosis In
- Page 135 and 136: Forms All required and recommended
- Page 137 and 138: High-Risk Groups Certain factors id
- Page 139 and 140: Diagnosis of Latent Tuberculosis In
- Page 141 and 142: continually exposed to populations
- Page 143 and 144: Administration of the Tuberculin Sk
- Page 145 and 146: See “Two-Step Tuberculin Skin Tes
- Page 147 and 148: See “Live-Virus Vaccines” under
- Page 149 and 150: For more information on IGRAs and t
- Page 151 and 152: Table 5: TARGETED TESTING FOR LATEN
- Page 153 and 154: Resources and References Resources
- Page 155 and 156: Treatment of Latent Tuberculosis In
- Page 157 and 158: Policy Detailed information on the
- Page 159 and 160: Window period prophylaxis is treatm
- Page 161 and 162: Regimens Identify an appropriate re
- Page 163 and 164: Dosages Once the appropriate regime
- Page 165 and 166: Side Effects and Adverse Reactions
- Page 167 and 168: If a patient reports to a healthcar
- Page 169 and 170: Antituberculosis Drug Rifampin (RIF
- Page 171 and 172: DOT is strongly encouraged for thos
- Page 173 and 174: Table 7 describes the duration of t
- Page 175 and 176: Alcoholism Alcohol-Related Treatmen
- Page 177: Medication Administration and Pharm
- Page 181 and 182: 24 CDC . “Recommendations for Use
- Page 183 and 184: Diagnosis and Treatment of Latent T
- Page 185 and 186: All children suspected or diagnosed
- Page 187 and 188: Latent Tuberculosis Infection (LTBI
- Page 189 and 190: History of BCG vaccination is not a
- Page 191 and 192: Because of their higher specificity
- Page 193 and 194: Table 3: COUNTRIES AND AREAS WITH A
- Page 195 and 196: Treatment of Latent TB Infection (L
- Page 197 and 198: For consultation regarding the trea
- Page 199 and 200: Monitoring DOT is mandatory for INH
- Page 201 and 202: For young infants, some experts rec
- Page 203 and 204: TABLE 8: SIGNS AND SYMPTOMS OF PULM
- Page 205 and 206: Treatment of Tuberculosis Basic pri
- Page 207 and 208: Regime n 1 2 3 ❺ Table 10: FOUR T
- Page 209 and 210: † 35 Table 11: DOSES*OF FIRST-LIN
- Page 211 and 212: Monitoring Response to Treatment Ch
- Page 213 and 214: Child Care and Schools: Children wi
- Page 215 and 216: Other TB medications are not commer
- Page 217 and 218: 10 Centers for Disease Control and
- Page 219 and 220: Case Management CONTENTS Introducti
- Page 221 and 222: patient-centered approach to case m
- Page 223 and 224: Alaska TB Program: Timeline for the
- Page 225 and 226: For assistance with language issues
- Page 227 and 228: Ascertain the extent of TB illness
National <strong>Tuberculosis</strong> Controllers Association–National <strong>Tuberculosis</strong> Nurse<br />
Consultant Coalition. <strong>Tuberculosis</strong> Nursing: A Comprehensive Guide to Patient Care<br />
(Atlanta, GA;1997:47–51, 63–64).<br />
CDC. Module 4: “Treatment <strong>of</strong> <strong>Tuberculosis</strong> and <strong>Tuberculosis</strong> Infection” (Self-<br />
Study Modules on <strong>Tuberculosis</strong> [Division <strong>of</strong> <strong>Tuberculosis</strong> Elimination Web Site]; 2008).<br />
Available at: http://www.cdc.gov/tb/education/ssmodules/default.htm<br />
Saukkonen, J. Et al. An Official ATS <strong>State</strong>ment: Hepatotoxicity <strong>of</strong><br />
Antituberculosis Therapy. Am J Respir Crit Care Med. 2006:174, 935-952. Available at<br />
http://ajrccm.atsjournals.org/cgi/reprint/174/8/935.pdf<br />
Adherence<br />
CDC. Module 9: “Patient Adherence to <strong>Tuberculosis</strong> Treatment” (Self-Study<br />
Modules on <strong>Tuberculosis</strong>. Division <strong>of</strong> <strong>Tuberculosis</strong> Elimination Web Site; 1999).<br />
Available at: http://www.cdc.gov/tb/education/ssmodules/module9/ss9contents.htm<br />
Module is entirely devoted to assessing and promoting adherence. It covers the<br />
many areas that need to be addressed, such as:<br />
Case management: assigning responsibility to the healthcare worker<br />
Communication and problem-solving skills<br />
Education <strong>of</strong> the patient<br />
Using interpreters when needed<br />
Using incentives (rewards) and enablers (things that remove barriers for patients)<br />
Using directly observed therapy (DOT)<br />
CDC. Improving Patient Adherence to <strong>Tuberculosis</strong> Treatment. (1994)<br />
National <strong>Tuberculosis</strong> Controllers Association–National <strong>Tuberculosis</strong> Nurse<br />
Consultant Coalition. <strong>Tuberculosis</strong> Nursing: A Comprehensive Guide to Patient Care<br />
(Atlanta, GA; 1997:69–84).<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Treatment <strong>of</strong> Latent <strong>Tuberculosis</strong> Infection<br />
Revised November 2012<br />
8.25